Pediatric IBD patients show medication and disease activity dependent changes in NK cell and CD4 memory T cell populations.
azathioprine
crohn’s disease
memory T cells
natural killer cells
ulcerative colitis
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
12
2022
accepted:
14
06
2023
medline:
17
7
2023
pubmed:
17
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
CD4+ memory T cells facilitate long-termed adaptive immune responses while NK cells are predominately rapid effector cells with significant functions for both intestinal homeostasis and inflammation. We wanted to study both populations in health and pediatric inflammatory bowel disease (IBD) and correlate them with disease activity and medication. We performed flow cytometric analyses of peripheral blood CD4 + CD45RO+ memory T cells and CD3-CD16 + CD56+ NK cells in 30 patients with IBD and 31 age-matched controls and correlated percentages of subsets with disease activity (PUCAI/PCDAI) and medication. We found a significant reduction of peripheral NK cells in overall IBD patients with both clinical remission and disease activity, which was even more pronounced in patients treated with azathioprine. Otherwise, circulating CD4+ memory T cell populations were significantly enhanced in active IBD compared to controls. Enhancement of memory T cells was particularly found in new onset disease and correlated with disease activity scores. Our single center cohort confirms previous results showing enhanced memory T cell populations in pediatric IBD patients, which correlate with disease activity scores. CD4+ memory T cells are a relevant pathogenic leukocyte population for disease development and perpetuation in IBD. In addition, we found a decrease of NK cells in IBD patients, which was pronounced by use of azathioprine. Surveillance of both cellular populations could possibly serve as biomarker for therapy control in pediatric IBD.
Identifiants
pubmed: 37456566
doi: 10.3389/fped.2023.1123873
pmc: PMC10345343
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1123873Informations de copyright
© 2023 Pappa, Mührer, Gast, Hebbar Subramanyam, Ohl, Muschaweck, Wagner, Wenzl and Tenbrock.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cells. 2020 Jan 02;9(1):
pubmed: 31906479
Gut. 2014 Oct;63(10):1578-86
pubmed: 24398881
Gastroenterology. 1996 Apr;110(4):1008-19
pubmed: 8612987
Front Immunol. 2022 Jun 23;13:893803
pubmed: 35812429
J Crohns Colitis. 2019 Jul 25;13(7):905-915
pubmed: 30715262
Cochrane Database Syst Rev. 2016 Oct 26;10:CD000545
pubmed: 27783843
Nat Rev Immunol. 2007 Sep;7(9):678-89
pubmed: 17717539
JAMA Pediatr. 2015 Nov;169(11):1053-60
pubmed: 26414706
J Crohns Colitis. 2021 Aug 2;15(8):1316-1325
pubmed: 33460436
Nature. 2012 Nov 1;491(7422):119-24
pubmed: 23128233
World J Gastroenterol. 2017 May 14;23(18):3240-3251
pubmed: 28566883
Gastroenterology. 2008 Oct;135(4):1114-22
pubmed: 18725221
J Allergy Clin Immunol. 2023 Jan;151(1):280-286.e2
pubmed: 36122787
J Intern Med. 2012 Nov;272(5):411-29
pubmed: 22946654
J Gastroenterol. 2018 Sep;53(9):1048-1064
pubmed: 29869016
Gastroenterology. 2017 Nov;153(5):1320-1337.e16
pubmed: 28782508
Mediators Inflamm. 2020 Feb 19;2020:6401969
pubmed: 32148442
Front Pediatr. 2021 Mar 18;9:640497
pubmed: 33816403
J Immunol. 2009 Oct 15;183(8):5059-68
pubmed: 19786550
Arch Immunol Ther Exp (Warsz). 2020 Apr 4;68(2):12
pubmed: 32248339
Gastroenterology. 2007 Jan;132(1):176-89
pubmed: 17241870
J Clin Immunol. 2004 Mar;24(2):185-96
pubmed: 15024186
World J Gastroenterol. 2010 Dec 21;16(47):6001-9
pubmed: 21157977
Aliment Pharmacol Ther. 2011 Jan;33(1):115-26
pubmed: 21083588
J Immunol. 1998 Oct 1;161(7):3256-61
pubmed: 9759840